Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

AppleMed Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$1,282,986

168 payments

Through program year 2025, AppleMed Research Group LLC is reported as receiving $1,282,986 in research payments, across 168 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $102,899 41
2024 Research $203,390 51
2023 Research $242,338 29
2022 Research $193,243 20
2021 Research $434,057 22
2020 Research $37,434 1
2019 Research $69,625 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biohaven Pharmaceuticals, Inc. $471,492 23 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $372,134 70 payments
  3. Pfizer Inc. $358,123 69 payments
  4. Ironwood Pharmaceuticals, Inc $69,625 4 payments
  5. Bausch Health US, LLC $11,612 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens $321,646 19 payments
  2. BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $261,781 13 payments
  3. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $199,457 6 payments
  4. A Phase 4 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens $113,233 3 payments
  5. A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $92,213 10 payments
  6. C3718-302 $69,625 4 payments
  7. A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With A History of Inadequate Response to Oral Preventive Medications $67,139 66 payments
  8. A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $43,217 12 payments
  9. A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $37,434 1 payment
  10. Phase 3 Multicenter Openlabel Study to Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $22,550 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record